



## SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. (INDIA)  
Ph. : 040-23204230, 23204273  
Fax : 0091-40-23204273  
CIN : L24230TG1994PLC018786  
E-mail: sigachilaboratories@yahoo.co.in

Date: 13.02.2018

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4th Floor  
Plot No.62, G- Block, Opp Trident Hotel,  
Bandra Kuria Complex, Bandra (E)  
Mumbai — 400 098

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 13<sup>th</sup> February, 2018 – Submission of Un audited financial results for the quarter and nine months ended 31<sup>st</sup> December, 2017- Reg.

Ref: Disclosure under Regulation 30, 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e. Tuesday, 13<sup>th</sup> February, 2018 has inter-alia considered and approved the Un-audited Financial Results under IND AS for the quarter and nine months ended 31<sup>st</sup> December, 2017. The Un-audited Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2017 along with Limited Review Report of the Statutory Auditors are enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sigachi Laboratories Limited

  
(Kuradia Ajay Kumar)  
Company Secretary



Meeting Commenced at 03.00 P.M.  
Meeting Concluded at 04.00 P.M.

**SIGACHI LABORATORIES LIMITED**  
 Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gurnandidala Mandal, Sanga Reddy District, Telangana.  
 Tel No.: 040 - 23204230 / 23204273,  
 Website: www.sillab.com, Email: sigachilaboratories@yahoo.co.in  
 CIN:L24230TG1994PLC018786

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2017.**

S.No	Particulars	Quarter ended				Nine Months ended		Year ended	
		31.12.2017		30.09.2017		31.12.2017		31.03.2017	
		Un Audited	Audited	Un Audited	Audited	Un Audited	Audited	Un Audited	Audited
1	<b>Income</b>								
	a. Revenue from operations	64.69	47.16	18.63	157.02	82.99	154.00		
	b. Other income	12.64	4.36	4.29	19.06	43.35	50.79		
2	<b>Total Income (a+b)</b>	<b>77.33</b>	<b>51.52</b>	<b>22.92</b>	<b>176.08</b>	<b>126.34</b>	<b>204.79</b>		
3	<b>Expenses</b>								
	a) Cost of Materials Consumed	-	-	-	-	-	-		
	b) Change in Inventories	-	-	-	-	-	-		
	c) Employee benefits expense	7.40	6.98	5.77	20.72	16.07	21.94		
	d) Finance costs	-	-	-	-	-	-		
	e) Depreciation and amortization expense	3.35	2.89	2.94	9.02	8.82	11.97		
	f) Other expenses	15.10	7.96	2.83	26.85	15.84	29.83		
	<b>Total Expenses</b>	<b>25.85</b>	<b>17.83</b>	<b>11.54</b>	<b>56.59</b>	<b>40.73</b>	<b>63.74</b>		
4	<b>Profit before tax (2-3)</b>	<b>51.48</b>	<b>33.69</b>	<b>11.38</b>	<b>119.49</b>	<b>85.61</b>	<b>141.06</b>		
5	<b>Tax expense</b>								
	(1) Current tax	8.31	5.25	7.20	17.81	17.09	22.98		
	(2) Deferred tax	(5.22)	4.95	0.57	0.28	1.72	2.29		
6	<b>Net Profit for the Period (4-5)</b>	<b>48.39</b>	<b>23.49</b>	<b>3.61</b>	<b>101.40</b>	<b>66.80</b>	<b>115.78</b>		
7	<b>Other comprehensive income (OCI)</b>								
	(a) (i) Items that will not be reclassified to profit or loss	83.25	36.53	(25.29)	144.65	103.40	180.33		
	(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-	-	-		
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-		
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-		
	<b>Total Other Comprehensive income</b>	<b>83.25</b>	<b>36.53</b>	<b>(25.29)</b>	<b>144.65</b>	<b>103.40</b>	<b>180.33</b>		
8	<b>Total Comprehensive income (6+7)</b>	<b>131.64</b>	<b>60.02</b>	<b>(21.68)</b>	<b>246.05</b>	<b>170.20</b>	<b>296.11</b>		
	<b>Earnings per equity share</b>								
	(Face value of Rs. 10/- each)								
	(1) Basic	0.72	0.35	0.05	1.50	0.99	1.71		
	(2) Diluted	0.72	0.35	0.05	1.50	0.99	1.71		

Segment wise Revenue, Results and Capital Employed for the quarter and nine months ended 31st December, 2017

Particulars	Quarter Ended			Nine Months Ended			Year ended
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.12.2016	31.03.2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>Segment Revenue</b>							
a) Bulk Drugs and Intermediates	32.19	21.90	22.50	78.10	60.00	60.00	91.50
b) Investments	45.14	29.62	0.42	97.98	66.34	66.34	113.29
<b>Total</b>	<b>77.33</b>	<b>51.52</b>	<b>22.92</b>	<b>176.08</b>	<b>126.34</b>	<b>126.34</b>	<b>204.79</b>
Less: Inter Segment Revenue							
Net sales/Income From Operations	77.33	51.52	22.92	176.08	126.34	126.34	204.79
<b>Segment Results Profit/ (Loss) before tax and finance Cost from each segment</b>							
a) Bulk Drugs and Intermediates	23.90	18.89	19.01	63.19	49.77	49.77	69.93
b) Investments	45.14	29.62	0.42	97.98	66.34	66.34	113.30
<b>Total</b>	<b>69.04</b>	<b>48.51</b>	<b>19.43</b>	<b>161.17</b>	<b>116.11</b>	<b>116.11</b>	<b>183.23</b>
Less: (i) Finance Costs							
(ii) Other Un-allocable Expenditure net off	17.56	14.82	8.05	41.68	30.50	30.50	42.17
(iii) Un-allocable income							
<b>Total Profit Before Tax</b>	<b>51.48</b>	<b>33.69</b>	<b>11.38</b>	<b>119.49</b>	<b>85.61</b>	<b>85.61</b>	<b>141.06</b>
<b>Capital Employed</b>							
(Segment assets – Segment Liabilities)							
a) Bulk Drugs and Intermediates	414.66	317.17	386.71	414.66	386.71	386.71	335.23
b) Investments	1,625.09	1,591.90	1,282.27	1,625.09	1,282.27	1,282.27	1,463.95
<b>Total</b>	<b>2,039.75</b>	<b>1,909.07</b>	<b>1,668.98</b>	<b>2,039.75</b>	<b>1,668.98</b>	<b>1,668.98</b>	<b>1,799.18</b>

**Notes:**

- The above results were reviewed by the Audit Committee and taken on record and approved by the Board of Directors at their respective meetings held on 13th February, 2018. The financial results for the Quarter and nine months ended 31st December, 2017 have been subjected to limited review by the company's Statutory Auditor.
- The company has adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued there under. The date of Transition to Ind AS is 1st April, 2017 and accordingly these unaudited financial results have been prepared in accordance with the recognition and measurements principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.

**Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter and nine months ended 31.12.2016**

Particulars	Quarter Ended	Nine months ended
	31.12.2016	31.12.2016
	(Unaudited)	(Unaudited)
<b>Net profit under previous GAAP</b>	19.11	79.79
a) Impact on current and deferred taxes on Un absorbed business losses	(0.57)	(1.72)
b) Impact on account of fair value measurement of Investments other than equity instrument	(14.93)	(11.27)
<b>Net profit under Ind AS</b>	<b>3.61</b>	<b>66.80</b>

- The financial results and other financial information for the Quarter ended 31st December, 2016 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provided true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit.
- There is possibility that these Quarterly financial results may require adjustment before constituting the final Ind AS financial Statements as of end for the year ending 31st March, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of 1 or more optional exemptions from full retrospective application as permitted under Ind AS 101.
- The Company operates in two segments and the results pertain to two segments.
- Figures for the previous period have been regrouped / reclassified wherever necessary to conform to the current period's presentation.

Place: Hyderabad  
Date: 13-02-2018

for SIGGACHI LABORATORIES LIMITED

Sd/-  
Chairman & Managing Director  
DIN:00917498

**niranjan & narayan**  
Chartered Accountants

first floor, h.no: 7-1-28/1/A/21  
shyamkaran road, ameerpeta  
hyderabad - 500 016  
tel : 23741774, cell : 9490189487  
email : caniranjan@yahoo.com  
www.nncas.com

INDEPENDENT AUDITORS' REVIEW REPORT

To

The Board of Directors  
Sigachi Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sigachi Laboratories Limited ("the company") for the quarter and Nine months ended 31<sup>st</sup> December, 2017 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review of the statement in accordance with Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

3. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the applicable Indian Accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 13.02.2018



For NIRANJAN AND NARAYAN,  
Chartered Accountants  
Firm Regn.No.005899S

*M. Nirajan*  
M. Nirajan

Partner - Membership No. 029552